Q32 Bio Inc. 8-K

What Happened
Q32 Bio Inc. announced on July 14, 2026 that it entered into an underwriting agreement with Morgan Stanley, Jefferies, Cantor Fitzgerald and Oppenheimer to sell common stock and pre‑funded warrants. The Offering includes 6,027,399 firm shares of common stock at $18.25 per share and pre‑funded warrants to purchase up to 4,931,506 shares at $18.2499 each. The underwriters have a 30‑day option to purchase up to an additional 1,643,835 shares. The Offering is expected to close on July 16, 2026. Estimated net proceeds are approximately $187.6 million, or $215.8 million if the option is fully exercised. Proceeds are intended for working capital, including research, clinical development and commercialization to support advancement of bempikibart.

Key Details

• Underwriting agreement dated July 14, 2026 with Morgan Stanley & Co. LLC, Jefferies LLC, Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc.
• Firm shares: 6,027,399 common shares at $18.25 per share; Pre‑Funded Warrants for up to 4,931,506 shares at $18.2499 each.
• Underwriters’ 30‑day option to buy up to 1,643,835 additional shares.
• Pre‑Funded Warrants exercisable for one share at $0.0001 (cash or cashless), subject to ownership limits (default 4.99% or 9.99%; adjustable up to 19.99% with notice). Warrants will not be listed.
• Offering made under the Company’s shelf registration (Form S-3); legal opinion from Goodwin Procter LLP is filed as an exhibit.

Why It Matters
This financing provides Q32 Bio with immediate capital to fund operations and advance its lead program, bempikibart, through further clinical and commercialization work. For investors, the raise reduces near‑term financing risk but will dilute existing shareholders when shares and warrants are issued or exercised. If the underwriters’ option is exercised, the company would receive additional capital and produce greater dilution. The pre‑funded warrants allow purchasers to acquire shares at a nominal exercise price, which could lead to material future share issuance.